All News

Nurx reproductive access survey reveals 28% of women do not believe their right to contraception is protected.

The updates are based on nationwide reports of extreme pain during IUD insertion.

AI and other technologies, in conjunction with ASHP’s guidelines, can improve drug diversion monitoring and outcomes.

Investigators analyzed a series of disease-modifying therapies in a multi-decade trial.

The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care.

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.

Durvalumab is a human monoclonal antibody that targets and binds to PD-L1 to interrupt tumor immune-evasion tactics.

Setting realistic goals can improve patients’ medication adherence and self-efficacy.

A federal and state policy expert discusses the announcement from the Centers for Medicare & Medicaid Services on the agreement to lower prices for 10 selected drugs due to the Inflation Reduction Act.

The current outbreak has infected more than 14,000 people and spread to 13 different African countries.

Olivia Kinney, a national pharmacy practice manager at Kroger, discusses strategies for pharmacists to effectively address vaccine hesitancy by building trust with patients.

RSV and influenza vaccines demonstrated hemagglutination inhibition titers that were noninferior to those with sequential administration.

Kelsea Seago, PharmD, discusses the crucial role of pharmacists in managing chimeric antigen receptor (CAR) T-cell therapy resistance.

Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

The decision is based positive data from the Deltacel-01 clinical trial.

AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.

This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

Some individuals are still unaware of the significance of routine oral hygiene and its link to overall health

Tune into this episode of “Public Health Matters” to learn about how Healthcare Advocate Summit, created by advocates for advocates, is involved in the discussion on improving access to health care.

Axatilimab-csfr (Niktimvo, Incyte Corporation) is a colony stimulating factor-1 receptor-blocking antibody for the treatment of chronic graft-versus-host disease (cGVHD).

The decision is based on clinical findings demonstrating seladelpar’s ability to effectively regulate of alkaline phosphatase values in patients.

Response to intravenous immunoglobulin treatment and analysis of neurofilament light chains in patients could be used as prognostic indicators of Guillain-Barre syndrome.

Individuals with Parkinson disease reported a decrease in bacterial genes for biosynthesis of riboflavin (vitamin B2) and biotin (vitamin B7).

The seroprotection rate of antibody titers was 100% against the 3 viruses, and geometric mean titer also increased from administration to day 43.

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

Roszak highlighted pharmacy data interoperability and food is medicine programs as 2 examples of innovative projects at the National Association of Chain Drug Stores.

Pharmacists play a vital role in therapy selection.

Patient fears can be mitigated by pharmacists who use targeted communication strategies to bolster acceptance.